LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-28 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Materials and samples from the original experiments remained in 2017 under the care of Miller's former student, Jeffrey Bada, a professor at the UCSD, Scripps Institution of Oceanography who also conducts origin of life research. As of 2013, the apparatus used to conduct the experiment was on display at the Denver Museum of Nature and Science.
=== Invention of products === In the 18th century, the potato was actively studied in all its practical aspects: cultivation and reproduction, diseases, use as a food for animals and as a vegetable for humans. Its use was also considered in the same way as that of cereals which produce flour – and therefore bread – but also alcohol. Other uses and by-products were born, some of which still exist in the 21st century.
=== Recombinant antibodies === Recombinant antibodies (rAbs) are produced in vitro by the means of expression systems based on mammalian cells. Their monospecific binding to a specific epitope makes rAbs eligible not only for research purposes, but also as therapy options against certain cancer types, infections and autoimmune diseases.
Actinidia chinensis var. deliciosa (kiwifruit) Ambrosia artemisiifolia (short ragweed) Ananas comosus (pineapple) Apium graveolens (celery) Arachis hypogaea (peanut) Artemisia vulgaris (mugwort) Betula verrucosa (European white birch) and Betula pendula (silver birch) Capsicum annuum (bell pepper) Chenopodium album (pigweed) Citrus sinensis (sweet orange) Corylus avellana (hazel) Cucumis melo (muskmelon) Daucus carota (carrot) Glycine max (soybean) Helianthus annuus (sunflower) Hevea brasiliensis (para rubber tree [latex]) Malus domestica (apple) Olea europaea (olive) Phleum pratense (timothy grass) Phoenix dactylifera (date palm) Prunus persica (peach) Pyrus communis (pear) Salsola kali (Russian thistle) Sinapis alba (yellow mustard) Solanum lycopersicum (tomato)
Sources: en.wikipedia.org
Other studies replacing the amide bonds with ester bonds also confirm that the end section is important in binding and activation. The Y2 receptors are located in the hippocampus, sympathetic and parasympathetic nerve fibres, intestines, and certain blood vessels, and have been implicated in regulating food intake and gastric emptying. As a result of this, the Y2 receptor is considered a target for the treatment of obesity and type II diabetes.
=== Starting an SNRI regimen === Due to the extreme changes in noradrenergic activity produced from norepinephrine and serotonin reuptake inhibition, patients that are just starting an SNRI regimen are usually given lower doses than their expected final dosing to allow the body to acclimate to the drug's effects. As the patient continues along at low doses without any side-effects, the dose is incrementally increased until the patient sees improvement in symptoms without detrimental side-effects.
The NCI continued to commission work to collect more Taxus bark and to isolate increasing quantities of taxol. By 1969, 28 kg (62 lb) of crude extract had been isolated from almost 1,200 kg (2,600 lb) of bark, although this ultimately yielded only 10 g (0.35 oz) of pure material, but for several years, no use was made of the compound by the NCI. In 1975, it was shown to be active in another in vitro system; two years later, a new department head reviewed the data and finally recommended taxol be moved on to the next stage in the discovery process. This required increasing quantities of purified taxol, up to 600 g (21 oz), and in 1977 a further request for 7,000 lb (3,200 kg) of bark was made. In 1978, two NCI researchers published a report showing that taxol was mildly effective in leukaemic mice. In November 1978, taxol was shown to be effective in xenograft studies. Meanwhile, taxol began to be well known in the cell biology, as well as the cancer communities, with a publication in early 1979 by Susan B. Horwitz, a molecular pharmacologist at Albert Einstein College of Medicine, showing that taxol had a previously unknown mechanism of action involving the stabilization of microtubules. Together with formulation problems, this increased interest from researchers meant that, by 1980, the NCI envisaged needing to collect 20,000 lb (9,100 kg) of bark. Animal toxicology studies were completed by June 1982, and in November, the NCI applied for the IND necessary to begin clinical trials in humans.
While the UK was an early leader with the Modern Slavery Act 2015, techUK argues that the law has become an obsolete "reporting law" that allows companies to merely state they are doing nothing. They have called for the UK to adopt mandatory human rights due diligence laws, similar to the EU's Corporate Sustainability Due Diligence Directive, to force technology companies to meaningfully investigate and address human rights abuses.
=== South Africa === The species has been protected in South Africa since 1991; with laws banning both deliberate killing and selling. In the province of KwaZulu-Natal (KZN), the KwaZulu-Natal Sharks Board employs nets around protected beaches to mitigate the risk of shark attacks, though these are excluded from major aggregation sites. Population estimates have varied: a 1996 study estimated an average of 1,279 individuals between 1989 and 1993, while a 2004 study suggested the population had grown to 1,953 post-protection. A 2023 study concluded that white shark numbers off South Africa have remained stable since 1991, despite declines in sightings at Western Cape. Researchers suggested the population may be shifting eastward, potentially in response to orca predation. However, these findings are disputed; in 2024, it was noted that white shark catches in KZN have actually declined since 2010, casting doubt on the theory of an eastward migration.
Sources: en.wikipedia.org
Corn (maize) became a staple food in the southeast United States and in parts of Europe. A disease that was characterized by dermatitis of sunlight-exposed skin was described in Spain in 1735 by Gaspar Casal. He attributed the cause to poor diet. In northern Italy it was named pellagra from the Lombard language (agra = holly-like or serum-like; pell = skin). In time, the disease was more closely linked specifically to corn. In the US, Joseph Goldberger was assigned to study pellagra by the Surgeon General of the United States. His studies confirmed a corn-based diet as the culprit, but he did not identify the root cause. Nicotinic acid was extracted from the liver by biochemist Conrad Elvehjem in 1937. He later identified the active ingredient, referring to it as "pellagra-preventing factor" and the "anti-blacktongue factor." It was also referred to as "vitamin PP", "vitamin P-P" and "PP-factor", all derived from the term "pellagra-preventive factor". In the late 1930s, studies by Tom Douglas Spies, Marion Blankenhorn, and Clark Cooper confirmed that nicotinic acid cured pellagra in humans. The prevalence of the disease was greatly reduced as a result. In 1942, when flour enrichment with nicotinic acid began, a headline in the popular press said "Tobacco in Your Bread." In response, the Council on Foods and Nutrition of the American Medical Association approved of the Food and Nutrition Board's new names niacin and niacin amide for use primarily by non-scientists.
The hydrophobic effect can be quantified by measuring the partition coefficients of non-polar molecules between water and non-polar solvents. The partition coefficients can be transformed to free energy of transfer which includes enthalpic and entropic components, ΔG = ΔH - TΔS. These components are experimentally determined by calorimetry. The hydrophobic effect was found to be entropy-driven at room temperature because of the reduced mobility of water molecules in the solvation shell of the non-polar solute; however, the enthalpic component of transfer energy was found to be favorable, meaning it strengthened water-water hydrogen bonds in the solvation shell due to the reduced mobility of water molecules. At the higher temperature, when water molecules become more mobile, this energy gain decreases along with the entropic component. The hydrophobic effect depends on the temperature, which leads to "cold denaturation" of proteins. The hydrophobic effect can be calculated by comparing the free energy of solvation with bulk water. In this way, the hydrophobic effect not only can be localized but also decomposed into enthalpic and entropic contributions.
=== As an enzyme for catalytic activity === Cytochrome c has also been widely studied as an enzyme with peroxidase-like activity. Cytochrome c was conjugated to charged polymer to test its peroxidase-like activity. Inspired from natural examples of enzyme encapsulation in protein-based cage structures (Example: Carboxysomes, ferritin, and encapsulin), Cytochrome c was encapsulated in a 9 nm small self-assembling DNA binding protein from nutrient starved cells (Dps) protein cage using chimeric self-assembly approach. Authors observed unique catalytic activity behavior upon encapsulating enzyme inside a protein-cage, which was different from enzyme in solution. This was attributed to local microenvironment provided by Dps nanocage's interior cavity which is different than bulk.
=== EC 1.2.1 With NAD+ or NADP+ as acceptor === EC 1.2.1.1: deleted, replaced by EC 1.1.1.284, S-(hydroxymethyl)glutathione dehydrogenase and EC 4.4.1.22, S-(hydroxymethyl)glutathione synthase EC 1.2.1.2: Now EC 1.17.1.9, formate dehydrogenase EC 1.2.1.3: aldehyde dehydrogenase (NAD+) EC 1.2.1.4: aldehyde dehydrogenase (NADP+) EC 1.2.1.5: aldehyde dehydrogenase (NAD(P)+) EC 1.2.1.6: deleted (was benzaldehyde dehydrogenase) EC 1.2.1.7: benzaldehyde dehydrogenase (NADP+) EC 1.2.1.8: betaine-aldehyde dehydrogenase EC 1.2.1.9: glyceraldehyde-3-phosphate dehydrogenase (NADP+) EC 1.2.1.10: acetaldehyde dehydrogenase (acetylating) EC 1.2.1.11: aspartate-semialdehyde dehydrogenase EC 1.2.1.12: glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) EC 1.2.1.13: glyceraldehyde-3-phosphate dehydrogenase (NADP+) (phosphorylating) EC 1.2.1.14: Now EC 1.1.1.205, IMP dehydrogenase EC 1.2.1.15: malonate-semialdehyde dehydrogenase EC 1.2.1.16: succinate-semialdehyde dehydrogenase [NAD(P)+] EC 1.2.1.17: glyoxylate dehydrogenase (acylating) EC 1.2.1.18: malonate-semialdehyde dehydrogenase (acetylating) EC 1.2.1.19: aminobutyraldehyde dehydrogenase EC 1.2.1.20: glutarate-semialdehyde dehydrogenase EC 1.2.1.21: glycolaldehyde dehydrogenase EC 1.2.1.22: lactaldehyde dehydrogenase EC 1.2.1.23: 2-oxoaldehyde dehydrogenase (NAD+) EC 1.2.1.24: succinate-semialdehyde dehydrogenase (NAD+) EC 1.2.1.25: branched-chain α-keto acid dehydrogenase system EC 1.2.1.26: 2,5-dioxovalerate dehydrogenase EC 1.2.1.27: methylmalonate-semialdehyde dehydrogenase (CoA-acylating) EC 1.2.1.28: benzaldehyde dehydrogenase (NAD+) EC 1.2.1.29: aryl-aldehyde dehydrogenase EC 1.2.1.30: aryl-aldehyde dehydrogenase (NADP+) EC 1.2.1.31: L-aminoadipate-semialdehyde dehydrogenase EC 1.2.1.32: aminomuconate-semialdehyde dehydrogenase EC 1.2.1.33: (R)-dehydropantoate dehydrogenase EC 1.2.1.34: Now EC 1.1.1.131, mannuronate reductase EC 1.2.1.35: Now EC 1.1.1.203, uronate dehydrogenase EC 1.2.1.36: retinal dehydrogenase EC 1.2.1.37: Now EC 1.17.1.4, xanthine dehydrogenase EC 1.2.1.38: N-acetyl-γ-glutamyl-phosphate reductase EC 1.2.1.39: phenylacetaldehyde dehydrogenase EC 1.2.1.40: part of EC 1.14.13.15, cholestanetriol 26-monooxygenase EC 1.2.1.41: glutamate-5-semialdehyde dehydrogenase EC 1.2.1.42: hexadecanal dehydrogenase (acylating) EC 1.2.1.43: Now EC 1.17.1.10, formate dehydrogenase (NADP+) EC 1.2.1.44: cinnamoyl-CoA reductase EC 1.2.1.45: Now EC 1.1.1.312, 2-hydroxy-4-carboxymuconate semialdehyde hemiacetal dehydrogenase EC 1.2.1.46: formaldehyde dehydrogenase EC 1.2.1.47: 4-trimethylammoniobutyraldehyde dehydrogenase EC 1.2.1.48: long-chain-aldehyde dehydrogenase EC 1.2.1.49: 2-oxoaldehyde dehydrogenase (NADP+) EC 1.2.1.50: long-chain-fatty-acyl-CoA reductase EC 1.2.1.51: pyruvate dehydrogenase (NADP+) EC 1.2.1.52: deleted 2025 (was oxoglutarate dehydrogenase (NADP+)) EC 1.2.1.53: 4-hydroxyphenylacetaldehyde dehydrogenase EC 1.2.1.54: γ-guanidinobutyraldehyde dehydrogenase EC 1.2.1.55: Now EC 1.1.1.279, (R)-3-hydroxyacid-ester dehydrogenase EC 1.2.1.56: Now EC 1.1.1.280, (S)-3-hydroxyacid-ester dehydrogenase EC 1.2.1.57: butanal dehydrogenase EC 1.2.1.58: phenylglyoxylate dehydrogenase (acylating) EC 1.2.1.59: glyceraldehyde-3-phosphate dehydrogenase (NAD(P)+) EC 1.2.1.60: 5-carboxymethyl-2-hydroxymuconic-semialdehyde dehydrogenase EC 1.2.1.61: 4-hydroxymuconic-semialdehyde dehydrogenase EC 1.2.1.62: 4-formylbenzenesulfonate dehydrogenase EC 1.2.1.63: 6-oxohexanoate dehydrogenase EC 1.2.1.64: 4-hydroxybenzaldehyde dehydrogenase (NAD+) EC 1.2.1.65: salicylaldehyde dehydrogenase EC 1.2.1.66: Now EC 1.1.1.306, S-(hydroxymethyl)mycothiol dehydrogenase EC 1.2.1.67: vanillin dehydrogenase EC 1.2.1.68: coniferyl-aldehyde dehydrogenase EC 1.2.1.69: fluoroacetaldehyde dehydrogenase EC 1.2.1.70: glutamyl-tRNA reductase EC 1.2.1.71: succinylglutamate-semialdehyde dehydrogenase EC 1.2.1.72: erythrose-4-phosphate dehydrogenase EC 1.2.1.73: sulfoacetaldehyde dehydrogenase EC 1.2.1.74: abieta-7,13-dien-18-al dehydrogenase EC 1.2.1.75: malonyl CoA reductase (malonate semialdehyde-forming) EC 1.2.1.76: succinate-semialdehyde dehydrogenase (acylating) EC 1.2.1.77: 3,4-dehydroadipyl-CoA semialdehyde dehydrogenase (NADP+) EC 1.2.1.78: 2-formylbenzoate dehydrogenase EC 1.2.1.79: succinate-semialdehyde dehydrogenase (NADP+) EC 1.2.1.80: long-chain acyl-[acyl-carrier-protein] reductase EC 1.2.1.81: sulfoacetaldehyde dehydrogenase (acylating) EC 1.2.1.82: β-apo-4′-carotenal oxygenase EC 1.2.1.83: 3-succinoylsemialdehyde-pyridine dehydrogenase EC 1.2.1.84: alcohol-forming fatty acyl-CoA reductase EC 1.2.1.85: 2-hydroxymuconate-6-semialdehyde dehydrogenase EC 1.2.1.86: geranial dehydrogenase EC 1.2.1.87: propanal dehydrogenase (CoA-propanoylating) EC 1.2.1.88: L-glutamate γ-semialdehyde dehydrogenase EC 1.2.1.89: D-glyceraldehyde dehydrogenase (NADP+) EC 1.2.1.90: glyceraldehyde-3-phosphate dehydrogenase [NAD(P)+] EC 1.2.1.91: 3-oxo-5,6-dehydrosuberyl-CoA semialdehyde dehydrogenase EC 1.2.1.92: 3,6-anhydro-α-L-galactose dehydrogenase EC 1.2.1.93: formate dehydrogenase (NAD+, ferredoxin). Now EC 1.17.1.11, formate dehydrogenase (NAD+, ferredoxin) * EC 1.2.1.94: farnesal dehydrogenase EC 1.2.1.95: L-2-aminoadipate reductase EC 1.2.1.96: 4-hydroxybenzaldehyde dehydrogenase (++) EC 1.2.1.97: 3-sulfolactaldehyde dehydrogenase EC 1.2.1.98: 2-hydroxy-2-methylpropanal dehydrogenase EC 1.2.1.99: 4-(γ-glutamylamino)butanal dehydrogenase EC 1.2.1.100: 5-formyl-3-hydroxy-2-methylpyridine 4-carboxylic acid 5-dehydrogenase EC 1.2.1.101: L-tyrosine reductase EC 1.2.1.102: isopyridoxal dehydrogenase (5-pyridoxate-forming) EC 1.2.1.103: [amino-group carrier protein]-6-phospho-L-2-aminoadipate reductase EC 1.2.1.104: pyruvate dehydrogenase system EC 1.2.1.105: 2-oxoglutarate dehydrogenase system EC 1.2.1.106: [amino-group carrier protein]-5-phospho-L-glutamate reductase EC 1.2.1.107: glyceraldehyde-3-phosphate dehydrogenase (arsenate-transferring)
=== Development === All serous membranes found in the human body are formed ultimately from the mesoderm of the trilaminar embryo. The trilaminar embryo consists of three relatively flat layers of ectoderm, endoderm, and mesoderm. As the embryo develops, the mesoderm starts to segment into three main regions: the paraxial mesoderm, the intermediate mesoderm and the lateral plate mesoderm. The lateral plate mesoderm later splits in half to form two layers bounding a cavity known as the intraembryonic coelom. Individually, each layer is known as splanchnopleure and somatopleure.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.